NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nuritas

Nuritas

Private
DublinHealthcare & Life Scienceshttps://www.nuritas.com/

Last Round

Series C

Dec 20, 2024

Total Funding Raised

$146.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nuritas is a biotechnology company that utilizes a platform combining artificial intelligence and genomics to discover and unlock natural bioactive peptides for use in dietary supplements, functional foods, and cosmetics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Keywords

bioactive peptidesAI-powered discoveryfunctional ingredientspeptide discoveryfood techlongevity researchprecision nutritionnutraceuticalsAI drug discoverypeptide hydrolysatesbiotechingredient innovationclinical validationhealthy agingCPG

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuritas Comparables

Compare Nuritas with similar companies based on industry and business-model similarity.

Nuritas comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shiru
87%
Brightseed
83%
Protera
81%

Nuritas Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CDec 20, 2024
Series BNov 11, 2021
DebtNov 29, 2018
Series ADec 20, 2017
SeedDec 7, 2016
Seed
Oct 26, 2015

Key People

Founding team and executive leadership

John Casey

CEO

Executive Team

Nora K.

Founder, CEO

Founding Team

Andrew Franklyn-Miller

Chief Medical and Innovation Officer

Executive Team

Nuritas Investors

Notable investors and investment history

Nuritas investors
InvestorRounds
Cultivian Sandbox VenturesSeries B, Series A
Grosvenor Food & AgTechSeries C, Series B
McWin Capital PartnersSeries C
European Investment Bank GroupDebt
M&G InvestmentsSeries C
Cleveland AvenueSeries B
Clay CapitalSeries A, Seed, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2026

    Exhibiting at Vitafoods Europe 2026 in Barcelona.

  • Apr 24, 2026

    Vivatis Pharma will now cover Poland, Czech Republic, Slovakia, and Baltic markets.

Nuritas Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuritas Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuritas's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range72
Year Founded2014
Last FundingDec 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.